Formycon AG

Research Formycon AG (FYB) on Bullrun: market cap EUR 333.66M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerFYB
• ExchangeXETRA
• CountryGermany
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 333.66M
• Financial periodFY2025
• RevenueEUR 44.48M
• Revenue growth-36.2%
• Net income-EUR 64.70M
• Free cash flow-EUR 44.11M
• Gross margin8.0%

Valuation Snapshot

latest market cap is EUR 333.66M.

About Formycon AG

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names.

Frequently asked questions

What is Formycon AG's market cap?

Formycon AG's market capitalization is EUR 333.66M.

What does Formycon AG do?

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and...